Researchers have identified a protein and signaling pathway that could help overcome the developmental block preventing certain leukemia cells from maturing. Targeting this mechanism may offer a new strategy for treating aggressive blood cancers by encouraging immature cancer cells to develop into normal, specialized blood cells.

Under healthy conditions, immature blood cells in the bone marrow follow a carefully regulated maturation process. In some forms of leukemia, however, these precursor cells become stuck in an immature state, causing them to multiply uncontrollably and crowd out the healthy cells responsible for producing the body's normal blood supply.

Figure 1. Breaking Leukemia’s Developmental Block

Researchers have identified two key factors—a widely distributed protein and a critical cell signaling pathway—that help immature blood cells complete their normal development. The discovery suggests a potential way to drive certain leukemia cells out of their arrested, immature state and reduce their ability to survive and multiply. Figure 1 shows Breaking Leukemia’s Developmental Block.

The findings provide new insight into how blood cell maturation is regulated and could support the development of therapies that encourage leukemia cells to mature instead of remaining as dysfunctional precursor cells.

A Common Protein Holds the Key

Published in Cell Reports, the study investigated the long-standing mystery surrounding progranulin, a protein involved in cell growth, inflammation, and tissue repair. Although progranulin is one of the most highly expressed genes in human macrophages—immune cells that engulf pathogens—its specific role in these white blood cells had remained unclear.

Researchers found it challenging to study progranulin in mammals because the same gene is active throughout the body. Disabling the gene affects multiple tissues and biological processes simultaneously, making it difficult to determine the protein’s specific function in blood cell development and immune cells.

Using zebrafish, researchers overcame a major challenge in studying progranulin because the animals possess two separate versions of the gene, allowing scientists to isolate its role in blood cell development. Earlier work showed that one zebrafish progranulin gene is active only in blood cells and is essential for immature myeloid progenitor cells to develop into macrophages and neutrophils.

The team then tested whether progranulin could produce the same effect in human leukemia cells. By adding the protein through different methods, they aimed to trigger immature cancer cells to mature into functional white blood cells, a strategy that could eventually lead to new treatments by reducing the cells' ability to proliferate uncontrollably.

A Failed Test Reveals the Missing Pathway

Researchers traced the missing piece of the puzzle to the JAK2/STAT3 signaling pathway after studying zebrafish lacking the blood cell form of progranulin. They discovered that both progranulin and JAK2/STAT3 are essential for immature myeloid progenitor cells to develop into macrophages. When progranulin was added to human leukemia cells with active JAK2/STAT3 signaling, the previously blocked cells resumed maturation, completed their normal life cycle, and eventually died.

The findings suggest that restoring this pathway could become a promising therapeutic strategy for certain forms of leukemia by forcing cancer cells to mature instead of remaining trapped in an immature, disease-causing state. The study also highlights the importance of animal models, such as zebrafish, in uncovering complex biological interactions that cannot yet be fully replicated in laboratory-grown cell systems.

Two Macrophage Types, Different Roles

The study also identified two distinct types of embryonic macrophages, revealing that only one depends on both progranulin and the JAK2/STAT3 signaling pathway for its development. This macrophage population appears to play a greater role in tissue repair and regeneration, suggesting it could become an important target for future regenerative medicine and cell-based therapies.

The discovery may help researchers design more effective laboratory-grown macrophages by focusing on the specific cell type best suited for healing damaged tissues [1]. Although a leukemia treatment based on progranulin and JAK2/STAT3 is still many years away, the findings provide valuable insight into blood cell development and identify promising biological targets for future cancer and regenerative therapies.

References:

1. https://scitechdaily.com/what-it-takes-to-make-a-white-blood-cell-could-unlock-new-cancer-treatments/

Cite this article:

Janani R (2026), White Blood Cell Discovery May Unlock Future Cancer Therapies, AnaTechMaz, pp. 828